|1.||Más, R: 9 articles (01/2005 - 08/2000)|
|2.||Mendoza, Sarahí: 8 articles (01/2012 - 01/2003)|
|3.||Noa, Miriam: 8 articles (01/2012 - 01/2003)|
|4.||Más, Rosa: 8 articles (01/2012 - 01/2003)|
|5.||Mendoza, S: 7 articles (06/2008 - 01/2003)|
|6.||Noa, M: 7 articles (06/2008 - 01/2003)|
|7.||Mendoza, Nilda: 5 articles (01/2012 - 01/2003)|
|8.||Mendoza, N: 5 articles (06/2008 - 01/2003)|
|9.||Gámez, R: 5 articles (01/2005 - 01/2003)|
|10.||Mas, Rosa: 4 articles (09/2011 - 01/2003)|
06/01/2011 - "Over 3 years, D-003 treatment increased lumbar spine BMD (5.1%, p < 0.01) and improved osteoporosis-related quality of life scores as compared with placebo-treated controls. "
01/01/2005 - "However, the potential value of D-003 in treating or preventing osteoporosis deserves further clinical investigation."
01/01/2004 - "These results suggest that D-003 could be useful for managing corticosteroid-induced osteoporosis."
01/01/2004 - "In conclusion, D-003 (50 and 200 mg/kg/day) prevented bone loss and decreased bone resorption in ovariectomized rats, which suggests that this substance could be promising in preventing or treating osteoporosis."
01/01/2012 - "D-003 inhibits the mevalonate pathway, lipid peroxidation and prevents osteoporosis in rats through increasing the osteoclast apoptosis. "
01/01/2003 - "The objective of this study was to determine whether D-003 shows protective effects against ISO-induced myocardial necrosis in rats. "
01/01/2003 - "In the two experimental series, D-003 at 5 and 25 mg/kg significantly (p < 0.01) decreased the percentage of turgent cells and hepatocytes with necrosis and increased the percentage of normal hepatocytes with respect to positive controls in a dose-dependent manner. "
01/01/2003 - "It is concluded that D-003 shows a protective effect on the myocardial necrosis induced by ISO in rats."
01/01/2003 - "D-003 administered repeatedly for 10 days also decreased all myocardial necrosis indicators in a dose-dependent manner, with results effective from 25 mg/kg to the highest dose tested, indicating that the repeated dose scheme was more effective to prevent the damage. "
01/01/2003 - "D-003 administered as single doses dose-dependently decreased necrosis area, percent of infarct area, and the presence of polymorphonuclear cells (PMNs) in myocardial tissue, but only the reductions induced by 200 and 400 mg/kg were significant. "
01/01/2005 - "A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study."
01/01/2005 - "This randomized, double-blind study compares the efficacy and tolerability of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia. "
01/01/2004 - "However, since casein-induced hypercholesterolemia is also a consequence of a stimulation of cholesterol absorption in the lumen and an increase of the output of cholesterol associated with LDL, the effect of D-003 on cholesterol absorption and LDL synthesis by the liver should be investigated."
01/01/2004 - "Oral administration of D-003, a mixture of very long chain fatty acids prevents casein-induced endogenous hypercholesterolemia in rabbits."
01/01/2004 - "Taken together, these results show that the efficacy of D-003 in reducing casein-derived hypercholesterolemia could involve, at least partially, an inhibition of hepatic cholesterol biosynthesis, which may elicit a decreased cholesterol concentration in hepatocytes, preventing the loss of hepatic LDL receptors induced by casein administration. "
|4.||Spinal Cord Ischemia
01/01/2004 - "The increase of PgI(2) levels achieved in the D-003 treated animals could be an important mechanism in the protection against the spinal cord ischemia."
01/01/2004 - "New Zealand rabbits were treated during 10 days with D-003 (25 and 200 mg kg(-1)) and ASA (2 mg kg(-1)) before spinal cord ischemia. "
01/01/2004 - "Protective effect of D-003 on experimental spinal cord ischemia in rabbits."
01/01/2005 - "The present study investigated whether the effects of D-003 on bone resorption and osteoclast apoptosis are dose-dependent. "
06/01/2008 - "It is concluded that D-003 administered for 12 months prevented bone loss and decreased bone resorption in ovx rats, without evidences of impaired bone quality."
10/01/2007 - "In conclusions, D-003 orally given at 50 mg kg(-1), a dose that prevents bone loss and bone resorption in ovariectomized rats, did not display oestrogenic/anti-oestrogenic activity in-vivo, as assessed in the uterotrophic assay."
10/01/2007 - "D-003 has been shown to prevent bone loss and bone resorption in ovariectomized rats, and significantly improves bone resorption markers in postmenopausal women with reduced bone mineral density. "
01/01/2005 - "In conclusion, D-003 (5-200 mg/kg) orally administered at for 12 weeks prevented bone loss and bone resorption and increased osteoclast apoptosis in ovariectomized rats in a dose-dependent manner. "
|2.||LDL Receptors (LDL Receptor)
|5.||Arachidonic Acid (Vitamin F)
|9.||Fatty Acids (Saturated Fatty Acids)